home.aspx
 
EVENTS

AGRICULTURAL BIOTECHNOLOGY & ENGINEERING
AGRICULTURAL BIOTECHNOLOGY & ENGINEERING
January 29-30, 2020
Agricultural Biotechnology & Engineering Conference 2020 is a great platform for learning, exchanging opinions, and expanding one’s network enabled by live presentations followed by dynamic questions & answers sessions as well as panel discussions and workshops with keynote speakers.

Industrial Biotechnology and Bioprocessing
INDUSTRIAL BIOTECHNOLOGY AND BIOPROCESSING
February 17-18, 2020
Through a series of plenary sessions, workshops and breakout sessions, Industrial Biotechnology 2020 will provide a rigorous review of novel therapies, bio-products as well as report on the very latest findings in industrial biotechnology and bioprocessing research.

Terminus

SHARESHARESHARE
Terminus is the leader of the account-based movement and the crucial link that connects B2B marketing and sales teams with their ideal customers. The Terminus solution arms marketing teams with an account-centric platform that delivers the intelligence and automation needed to scale ABM and revolutionize the way B2B marketing is done. Hundreds of organizations worldwide, including Salesforce, GE, Verizon, 3M and CA Technologies, turn to Terminus to more effectively target, engage and grow their best-fit accounts. Terminus offers savvy marketers the technology and proven expertise to radically improve ABM strategies and campaigns, increasing ROI and producing exceptional results.
SHARESHARESHARE

RELATED NEWS


Methyl chemical groups dot lengths of DNA, helping to control when certain genes are accessible by a cell. In new research, UCLA scientists have shown that at the connections between brain cells—which often are located far from the central control centers of the cells—methyl groups also dot chains of RNA. This methyl markup of RNA molecules is likely key to brain cells' ability to quickly send signals to other cells and react to changing stimuli in a fraction of a second. To dict...
UNIVERSITY OF CALIFORNIA
READ MORE

New research from North Carolina State University sheds light on the ways in which environmental chemicals can affect vitamin D receptors (VDR). The work shows that compounds identified as possible VDR disruptors in the Tox21 database interact with VDR in vitro and supports the efficacy of high throughput screening programs to identify compounds of interest."Most people think of vitamin D as only a vitamin, but in the body vitamin D is converted to a hormone, so VDR is part of the endocrine...
PHYS.ORG
READ MORE

BioSense negotiated an option to license Neovacs’ Phase II-stage IFNα-Kinoid therapeutic vaccine candidate for treating systemic lupus erythematosus (SLE) in China and selected territories. Under terms of the deal, Neovacs could receive up to €65 million (approximately $68.5 million) in up-front and milestone payments, not including any future sales royalties. The deal is the second signed by Neovacs for the IFNα-Kinoid candidate. During late 2015, the firm inked a strateg...
GENENGNEWS
READ MORE

An immunotherapy combining Roche’s blood cancer drug Rituxan and an anti-CD47 drug developed at Stanford University shrank the cancers of half the patients in a small phase 1 trial. The patients, who had non-Hodgkin lymphoma, had all either failed or relapsed after undergoing at least two other types of treatment. Stanford University scientists created the CD47-targeting drug, known as Hu5F-G4 after they found in 2010 that “nearly all” cancer cells mask themselves from immune a...
AMIRAH AL IDRUS
READ MORE

Biogen presented new data from the Phase 3 ENDEAR study of SPINRAZA™ (nusinersen), which demonstrated a statistically significant reduction in the risk of death or permanent ventilation in SPINRAZA-treated infants with spinal muscular atrophy (SMA) compared to untreated infants. The data were presented at the British Paediatric Neurology Association (BPNA) annual conference in Cambridge, UK, 11-13 January 2017....
BIOGEN.COM
READ MORE

Israeli biotech Kamada has hit another hurdle in its marathon bid to bring the first inhaled treatment for alpha-1 antitrypsin (AAT) deficiency to market as an alternative to intravenous drugs.The company, which specializes in developing drugs from plasma proteins, says the FDA is still not fully satisfied with the proposed phase 3 protocol for nebulized AAT as a treatment for AAT deficiency, and it likely won’t be able to start the trial before the end of the year as hoped. Shares in the ...
FIERCEBIOTECH
READ MORE

EVENTS

AGRICULTURAL BIOTECHNOLOGY & ENGINEERING
AGRICULTURAL BIOTECHNOLOGY & ENGINEERING
January 29-30, 2020
Agricultural Biotechnology & Engineering Conference 2020 is a great platform for learning, exchanging opinions, and expanding one’s network enabled by live presentations followed by dynamic questions & answers sessions as well as panel discussions and workshops with keynote speakers.

Industrial Biotechnology and Bioprocessing
INDUSTRIAL BIOTECHNOLOGY AND BIOPROCESSING
February 17-18, 2020
Through a series of plenary sessions, workshops and breakout sessions, Industrial Biotechnology 2020 will provide a rigorous review of novel therapies, bio-products as well as report on the very latest findings in industrial biotechnology and bioprocessing research.